The osteoporosis treatment gap

Kanis, John A.; Svedbom, Axel; Harvey, Nicholas; McCloskey, Eugene V.

¹Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

²OptumInsight, Stockholm, Sweden

³Unit of Dermatology and Venerology, Department of Medicine, Karolinska University, Stockholm, Sweden

⁴Medical Research Council (MRC) Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

⁵National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University HospitalSouthampton National Health Service (NHS) Foundation Trust, Southampton, UK

Year

Entry

2004

Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jönsson B. Fracture risk following an osteoporotic fracture. Osteoporos Int. March 2004;15(3):175-179.

2001

Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA. January 17, 2001;285(6):320-323.

2013

Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA; EU review panel of the IOF. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. December 2013;8(1):137.

2004

Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. October 2004;15(10):767-778.

2013

Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO); Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. January 2013;24(1):23-57.

2014

Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. September 2014;29(9):1929-1937.

2013

Åkesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C. Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int. August 2013;24(8):2135-2152.

2010

Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Can Med Assoc J. November 23, 2010;182(17):1864-1873.

Year

Entry

2017

Curtis EM, Moon RJ, Harvey NC, Cooper C. The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone. November 2017;104:29-38.

2020

Ferrari S, Lewiecki EM, Butler PW, Kendler DL, Napoli N, Huang S, Crittenden DB, Pannacciulli N, Siris E, Binkley N. Favorable skeletal benefit/risk of long-term denosumab therapy: a virtual-twin analysis of fractures prevented relative to skeletal safety events observed. Bone. May 2020;134:115287.

2021

Malle O, Borgstroem F, Fahrleitner-Pammer A, Svedbom A, Dimai SV, Dimai HP. Mind the gap: incidence of osteoporosis treatment after an osteoporotic fracture: results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). Bone. January 2021;142:115071.

2021

Skjødt MK, Möller S, Hyldig N, Clausen A, Bliddal M, Søndergaard J, Abrahamsen B, Rubin KH. Validation of the fracture risk evaluation model (FREM) in predicting major osteoporotic fractures and hip fractures using administrative health data. Bone. June 2021;147:115934.

2019

Kanis JA, Cooper C, Rizzoli R, Reginster J-Y; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO); Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. January 2019;30(1):3-44.

2020

Parsons CM, Harvey N, Shepstone L, Kanis JA, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I, Holland R, Redmond NM, Howe A, Marshall T, Peters TJ, Torgerson D, O’Neill TW, McCloskey E, Cooper C; SCOOP Trial Group. Systematic screening using FRAX^® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporos Int. January 2020;31(1):67-75.

2020

Iconaru L, Smeys C, Baleanu F, Kinnard V, Moreau M, Cappelle S, Surquin M, Rubinstein M, Rozenberg S, Paesmans M, Karmali R, Bergmann P, Body JJ. Osteoporosis treatment gap in a prospective cohort of volunteer women. Osteoporos Int. July 2020;31(7):1377-1382.

2020

Kanis JA, Cooper C, Dawson-Hughes B, Harvey NC, Johansson H, Lorentzon M, McCloskey EV, Reginster J-Y, Rizzoli R; International Osteoporosis Foundation. FRAX and ethnicity. Osteoporos Int. November 2020;31(11):2063-2067.

2021

McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E, Hadji P, Payer J, Palmer K, Stad R, O’Kelly J, Papapoulos S. The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int. February 2021;32(2):251-259.

2021

Sagalla N, Colón-Emeric C, Sloane R, Lyles K, Vognsen J, Lee R. FRAX without BMD can be used to risk-stratify veterans who recently sustained a low trauma non-vertebral/non-hip fracture. Osteoporos Int. March 2021;32(3):467-472.